Cell and Gene Outsourcing

31. The Case For Non-Viral Circular Single-Stranded HDR Donors 8/13/2026

    Enable efficient, low-toxicity genome editing without viral vectors. This cell-free circular ssDNA platform preserves stem cell fitness while supporting scalable manufacturing.

32. GLP-1 Peptides Around The World 8/12/2026

    Explore how evolving regulations, supply constraints, and reimbursement models shape GLP-1 drug development across the U.S., Europe, and Asia.

33. Partnering For Success: Microbiological Testing In Contract Laboratories 8/12/2026

    Outsourcing microbiological testing goes beyond method selection. Learn how early lab engagement, redundancy planning, and regulatory alignment protect your release timelines and compliance.

34. Enhance Your Recruitment & Retention Strategy For Rare Kidney Disease Trials 8/10/2026

    Though the burdens of developing treatments for rare kidney diseases are high, data-driven recruitment strategies and experienced CRO teams will help ensure accessible trials with strong enrollment.

35. Why A Strong CMC Roadmap Is Essential For Cell Therapy Program Success 8/8/2026

    A structured regulatory roadmap and early management of manufacturing, materials, and assay testing help reduce risk and prevent costly delays in cell therapy development.

36. Late-Phase Process Development Capabilities Are Stronger Than Ever 8/8/2026

    Late-phase cell therapy programs require process control, automation, and characterization to improve consistency, reduce regulatory risk, and enable commercial-scale manufacturing.

37. How To Build A Cell Therapy CMC Roadmap 8/8/2026

    A structured, phase-appropriate regulatory roadmap helps cell therapy developers reduce risk, streamline manufacturing and testing, and avoid costly clinical delays.

38. Reducing The Time And Cost Of Robust Analytical Method Development 8/8/2026

    Design-of-experiment methodology accelerates cell therapy assay development, reducing costs and timelines while improving assay robustness, regulatory readiness, and data-driven decision-making.

39. A Rapid Approach To Streamlined CART Therapies And Reduced Cost 8/8/2026

    Advanced engineered vectors streamline cell therapy manufacturing, cutting operational steps by 40% and reducing material costs while maintaining T-cell purity and potency.

40. FUJIFILM Biotechnologies Capabilities Update July 2026: Gene Therapy 8/7/2026

    From process development to GMP manufacturing, our teams operate as one connected system to support your cell or gene therapy through every milestone.